Axon Enterprise, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Axon provides law-enforcement technology, including TASER conducted-energy devices, body-worn and in-car cameras, digital evidence management, cloud software, productivity tools, and real-time operations capabilities. The filing covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods. Operations are reported through the TASER and Software and Sensors segments.
Financial Performance and Position
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net sales | $413.6 million | $311.8 million | $1.131 billion | $853.8 million |
| Gross margin | $255.3 million; 61.7% | $193.3 million; 62.0% | $691.5 million; 61.1% | $523.0 million; 61.3% |
| Income from operations | $55.1 million; 13.3% | $32.1 million; 10.3% | $112.0 million; 9.9% | $70.7 million; 8.3% |
| Net income | $59.4 million | $12.1 million | $117.0 million | $118.0 million |
| Diluted EPS | $0.78 | $0.17 | $1.56 | $1.63 |
| Adjusted EBITDA | $91.6 million | $67.8 million | $238.3 million | $166.4 million |
Q3 revenue increased 32.7%, led by Software and Sensors revenue growth of 50.4% to $251.0 million. TASER revenue increased 12.2% to $162.6 million. Service revenue grew to $157.2 million, or 38.0% of total revenue, from $101.4 million, or 32.5%, in the prior-year quarter.
For the first nine months, revenue increased 32.5%. Software and Sensors revenue rose 48.2% to $680.0 million, while TASER revenue rose 14.3% to $451.3 million. Axon Evidence and cloud services revenue increased 55.0% to $401.0 million, and Axon Fleet Systems revenue increased 140.1% to $95.6 million.
Operating expenses increased 24.2% in Q3 and 28.1% for the nine-month period, primarily due to higher headcount, compensation, sales commissions, marketing, research and development, and stock-based compensation. R&D represented 18.6% of Q3 revenue and 19.4% of nine-month revenue.
Q3 net income benefited from a $4.1 million unrealized gain on the Cellebrite investment, compared with a $10.6 million unrealized loss in Q3 2022. Nine-month 2023 net income included a $71.9 million net unrealized impairment loss on a strategic investment and related warrants, a $29.6 million Cellebrite gain, and a $36.8 million discrete tax benefit primarily related to stock-based compensation vesting.
Cash provided by operating activities was $49.2 million for the first nine months, down from $104.2 million in 2022. Working-capital uses included increases of $182.5 million in receivables and contract assets, $59.6 million in inventory, and $64.6 million in prepaid and other assets, partly offset by a $118.3 million increase in deferred revenue.
Cash and cash equivalents were $406.0 million at September 30, 2023. Cash, cash equivalents, and available-for-sale investments totaled approximately $1.1 billion. The company had $192.6 million of available borrowing capacity under its $200.0 million revolving credit facility, after $7.4 million of letters of credit, and had no borrowings under the facility.
Convertible notes had a net carrying value of $676.3 million and $690.0 million principal outstanding. The notes bear interest at 0.50% and mature in December 2027. The reported net leverage ratio was 0.27 to 1.00, versus a covenant maximum of 3.50 to 1.00.
Material Changes Versus the Prior Comparable Period
- Revenue growth accelerated through strong adoption of TASER 10, Axon Body 4, Axon Fleet 3, and Axon Evidence and cloud services.
- Gross margin declined modestly as a percentage of revenue, primarily due to TASER 10 manufacturing ramp costs, a greater mix of lower-margin Sensors hardware, and higher professional-services costs.
- Operating margin improved to 13.3% in Q3 from 10.3%, reflecting revenue scale and operating-expense leverage.
- Nine-month net income was approximately flat despite substantially higher operating income because 2022 included significant investment gains, while 2023 included a strategic-investment impairment.
- Deferred revenue increased to $725.0 million from $608.0 million at December 31, 2022; contract assets increased to $339.2 million from $242.1 million.
- The company raised $94.7 million of net proceeds through its at-the-market equity offering and received $54.5 million from stock-option exercises. It paid $104.1 million for employee income and payroll taxes related to net-settled stock awards.
- During the nine months, the company completed an acquisition with total consideration of $23.9 million, recording $12.9 million of goodwill and $11.5 million of identifiable intangible assets.
Guidance, Outlook, Commentary, Risks, and Unusual Items
Management reported approximately $5.8 billion of remaining performance obligations as of September 30, 2023. It expects to recognize 15% to 25% over the next 12 months and generally the remainder over the following ten years. Recognition remains subject to delayed deployments, budget appropriations, and customer cancellation clauses.
Management believes available cash, investments, operating cash flows, and financing capacity will satisfy anticipated requirements for at least the next 12 months. The filing does not provide a clear quantitative full-year revenue or earnings forecast.
- A material weakness in internal control over financial reporting remained unremediated. The weakness relates to revenue recognition and deferred revenue controls associated with the 2021 ERP and quote-to-cash implementation. Disclosure controls and procedures were therefore deemed ineffective as of September 30, 2023.
- The company is defending product-liability lawsuits involving alleged wrongful death or personal injury. Management does not currently believe the matters will materially affect financial results, but litigation outcomes are inherently uncertain. Axon is self-insured for the first $5.0 million of post-2014 product claims.
- The FTC dismissed its administrative complaint regarding the Vievu acquisition in October 2023. Separate antitrust actions by Howell Township, Baltimore, and Augusta were pending and being consolidated.
- Government customers face budgetary, political, appropriation, termination-for-convenience, and open-bidding risks. These factors could delay or cancel contracts and affect the reported performance-obligation balance.
- Key operating risks include TASER 10 regulatory requirements and supply constraints, component availability and costs, cybersecurity or cloud outages, data privacy obligations, foreign-exchange exposure, product liability, and competition.
- A hypothetical 100-basis-point increase in interest rates would have reduced the fair value of the investment portfolio by approximately $2.1 million at September 30, 2023, before considering any realized losses.
Important Facts for Investors to Verify
- Whether the revenue-recognition and deferred-revenue material weakness is remediated and controls operate effectively in subsequent filings.
- The conversion, dilution, and cash-settlement implications of the $690.0 million 2027 convertible notes, including the associated warrants and note hedge.
- The sustainability of high Software and Sensors growth and the effect of professional-services mix, TASER 10 ramp costs, and hardware mix on consolidated margins.
- The conversion of the $5.8 billion performance-obligation balance into recognized revenue and cash, including the effect of government cancellation and appropriation clauses.
- Receivable and contract-asset collections, given the $339.2 million contract-asset balance and reduced year-to-date operating cash flow.
- Future fair-value changes or impairments in the company’s $240.3 million strategic-investment portfolio and marketable-securities holdings.
- Developments in product-liability, antitrust, regulatory, privacy, and cybersecurity matters and any related financial exposure.